← Eichor
Condition: Refractory Bladder Urothelial Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Bladder Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Uro
Phase 1/Phase 2 · 8 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06364956Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Phase 2 · 1 location(s) · Michael A. O'Donnell · NCT07322263
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.